Patient description: 19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain. She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HIV Infections Participants must be able to understand and comply with protocol requirements, instructions, and restrictions Participants must be likely to complete the study as planned Participants must be considered appropriate candidates for participation in an investigative clinical trial with oral medication (e.g., no active substance abuse, acute major organ disease, or planned long-term work assignments out of the country, etc.) HIV-1 infected men or women of >=18 years of age Must be on uninterrupted current regimen (either the initial or second combination antiretroviral therapy [cART] regimen) for at least 6 months prior to screening; Any prior switch, defined as a change of a single drug or multiple drugs simultaneously, must have occurred due to tolerability and/or safety concerns or access to medications, or convenience/simplification. Acceptable stable cART regimens prior to screening 2 NRTIs plus; INI (either the initial or second cART regimen), or an NNRTI (either the initial or second cART regimen), or a Boosted PI (or atazanavir unboosted) ( either the initial or second PI-based cART regimen) Documented evidence of at least two plasma HIV-1 RNA measurements <50 c/mL in the 12 months prior to Screening: one within the 6 to 12 month window, and one within 6 months prior to Screening Plasma HIV-1 RNA <50 c/mL at Screening A female may be eligible to enter and participate in the study if she is of : Non-child-bearing potential either defined as post-menopausal (12 months of spontaneous amenorrhea and >=45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or child-bearing potential with a negative pregnancy test at both Screening and Day 1 and agrees to use one of the following methods of contraception to avoid pregnancy: Complete abstinence from intercourse from 2 weeks prior to administration of study drug, throughout the study, and for at least 2 weeks after discontinuation of all study medications and completion of the Follow-up visit; Any intrauterine device (IUD) with published data showing that the expected failure rate is <1% per year (not all IUDs meet this criterion); Male partner sterilization with documentation of azoospermia prior to the female participant's entry into the study and this male is the sole partner for that participant. The documentation on male sterility can come from the site personnel's review of participant's medical records, medical examination, and/or semen analysis, or medical history interview provided by her or her partner; Approved hormonal contraception for participants randomly assigned to DTG + RPV arm (and for participants randomly assigned to CAR following switch to DTG + RPV at Week 52) or approved hormonal contraception plus a barrier method for participants assigned to CAR through Week 52. Approved hormonal contraception includes: Combined estrogen and progestogen oral contraceptive, Contraceptive subdermal implant, Injectable progestogen, Contraceptive vaginal ring, Percutaneous contraceptive patches; Any other method with published data showing that the expected failure rate is <1% per year. Any contraception method must be used consistently, in accordance with the approved product label during treatment with study drug and for at least 2 weeks after discontinuation of study drug and completion of the Follow-Up Visit. The investigator is responsible for ensuring that participants understand how to properly use these methods of contraception. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Note: these contraceptive requirements do not apply to females of reproductive potential with same sex partners only, when this is their preferred and usual lifestyle. All participants participating in the study should be counseled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g., male condom) and on the risk of HIV transmission to an uninfected partner Participants who are willing and able to understand requirements of study participation and provide signed and dated written informed consent prior to screening For participants enrolled in France: participants will be eligible for in this study only if either affiliated to or a beneficiary of a social security category  Exclusionary prior to screening or Day 1 Within 6 months prior to Screening and after confirmed suppression to <50 c/mL on current Antiretroviral therapy (ART regimen), any plasma HIV-1 RNA measurement >=50 c/mL Within the 6 to 12 month window prior to screening and after confirmed suppression to <50 c/mL, any plasma HIV-1 RNA measurement >200 c/mL Within the 6 to 12 month window prior to screening and after confirmed suppression to <50 c/mL, 2 or more plasma HIV-1 RNA measurements >=50 c/mL Any drug holiday during the window between initiating first HIV ART and 6 months prior to screening, except for brief periods (less than 1 month) where all ART was stopped due to tolerability and/or safety concerns Any switch to a second line regimen, defined as change of a single drug or multiple drugs simultaneously, due to virologic failure to therapy (defined as a confirmed plasma HIV-1 RNA measurement >=400 c/mL after initial suppression to <50 c/mL while on first line HIV therapy regimen). Exclusionary medical conditions Women who are pregnant, breastfeeding or plan to become pregnant or breastfeed during the study Any evidence of an active Centers for Disease Control and Prevention Category C disease. Exceptions cutaneous Kaposi's sarcoma not requiring systemic therapy and historic CD4+ lymphocyte counts of <200 cells per cubic millimeter (cells/mm^3) Participants with severe hepatic impairment (Class C) as determined by Child-Pugh Classification Unstable liver disease (as defined by the presence of any of the following: ascites, encephalopathy, coagulopathy, hypoalbuminemia, oesophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)